5-HT1D and 5-HT1E/1F Binding Sites in Depressed Suicides

Total Page:16

File Type:pdf, Size:1020Kb

5-HT1D and 5-HT1E/1F Binding Sites in Depressed Suicides Molecular Psychiatry (1997) 2, 314–321 1997 Stockton Press All rights reserved 1359–4184/97 $12.00 ORIGINAL RESEARCH ARTICLE 5-HT1D and 5-HT1E/1F binding sites in depressed suicides: increased 5-HT1D binding in globus pallidus but not cortex S Lowther1, CLE Katona2, MR Crompton3 and RW Horton1 1Department of Pharmacology and Clinical Pharmacology; 3Department of Forensic Medicine, St George’s Hospital Medical School, London SW17 0RE; 2Department of Psychiatry, University College London Medical School, London W1N 8AA, UK 5-HT1D and 5-HT1E/1F receptor binding sites were measured in brain samples obtained at post- mortem from suicide victims with a firm retrospective diagnosis of depression, and matched controls. In antidepressant-free suicides a significantly higher number of 5-HT1D receptors was found in globus pallidus. This was largely restricted to those suicides who died by violent means. This effect was not observed in antidepressant-treated suicides. No differences or trends in 5-HT1D binding were found in putamen, parietal or frontal cortex, in antidepressant- free or antidepressant-treated suicides. There were no differences in the number of 5-HT1E/1F receptors in any of the regions studied. Keywords: 5-HT1D receptor binding sites; 5-HT1E/1F receptor binding sites; suicide; depression; post- mortem brain tissue; antidepressant drugs; cerebral cortex; putamen; globus pallidus; basal ganglia Introduction receptors in a subgroup of subjects with no evidence of depressive symptoms, but not in a smaller subgroup There is abundant evidence that serotonergic function with well documented evidence of depression. is reduced in depression.1,2 Furthermore a consistent A number of 5-HT1D ligands and radioligands have feature of effective treatments is their ability to 10–13 been developed. The 5-HT a and 5-HT b recep- enhance serotonergic transmission.3 1D 1D tors have a very similar pharmacology, but can be dis- Seven classes of 5-HT (5-hydroxytryptamine, tinguished using ketanserin and ritanserin.14 [125I]GTI, serotonin) receptors are recognised; 5-HT have been 1–4 [3H]L-694,247 and [3H]GR 125743 are selective for 5- pharmacologically characterised, 5-HT were ident- 5–7 HT receptors,10,11,15–17 but do not distinguish the two ified by molecular biology and are less well character- 1D forms of the receptor. The 5-HT b receptor appears to ised.4 The 5-HT family is the largest with five subtypes 1D 1 be the dominant 5-HT receptor in human brain. termed 5-HT , 5-HT , 5-HT , 5-HT and 5-HT (the 1D 1A 1B 1D 1E 1F There are no selective ligands for 5-HT and 5-HT 5-HT receptor is now accepted as belonging to the 5- 1E 1F 1C receptors. They are labelled by [3H]5-HT and are HT family, and is termed 5-HT ).4 Two types of 5- 2 2C characterised by their low affinity for 5-carboxamido- HT1D receptor have been reported, termed 5-HT1Da and 5,6 tryptamine (5-CT), compared to other 5-HT1 recep- 5-HT b. The 5-HT receptor in the rat and mouse 1D 1B tors.18,19 In human frontal cortex these receptors is the species homologue of the 5-HT b receptor in 1D account for over 40% of the total 5-HT receptors.20 humans. 1 They have not been studied to date in relation to Studies of the possible involvement of 5-HT recep- 1 depression. tors in depression have been largely limited to the 5- In the present study we have used [3H]5-HT with HT receptor. The 5-HT receptor is of potential 1A 1D selective pharmacological blockade to examine 5-HT interest because it functions as a nerve terminal autore- 1D and 5-HT receptors (see Methods) in a group of ceptor, regulating the release of 5-HT.7,8 To date only 1E/1F suicides, restricted to those with a firm retrospective one study has examined 5-HT receptors in relation 1D diagnosis of depression. We have studied separately to depression. Arranz et al9 measured 5-HT receptor 1D those subjects who were free of antidepressants for at binding in frontal cortex of suicides. Although they least 3 months prior to death, and those in whom the found no significant difference overall compared to prescription of antidepressant drugs was clearly docu- matched controls, they found lower numbers of 5-HT 1D mented. Four brain regions were studied — frontal and parietal cortex, putamen and globus pallidus. We chose frontal cortex as this region is implicated in depression Correspondence: S Lowther, Department of Pharmacology and 21 Clinical Pharmacology, St George’s Hospital Medical School, and receptor changes have been reported. Another London SW17 0RE, UK. E-mail: slowtherKsghms.ac.uk cortical region, the parietal cortex, which has not been Received 10 October 1996; revised and accepted 23 January 1997 particularly implicated in depression, was chosen for 5-HT1D binding in depressed suicides S Lowther et al 315 comparative purposes. We have selected two areas of oughly mixed and stored in air-tight containers at the basal ganglia for study since structural and meta- −80°C until assayed. Brain areas studied were frontal bolic changes have been reported in affective dis- cortex (Brodmann area 10), parietal cortex (Brodmann orders.22–24 In human brain, the highest density of 5- area 7), putamen and globus pallidus. 20 HT1D receptors is found in globus pallidus, making it potentially interesting in relation to depression. Tissue preparation Membranes were prepared essentially as described by Cheetham et al.26 Frozen brain tissue was homogenised Materials and methods in ice-cold 0.25 M sucrose (1 : 20 w/v) using a motor- Subject selection driven teflon pestle (eight strokes at 120 rpm), and cen- Deaths recorded as suicide at Coroners’ inquest were trifuged (at 4°C) at 1000 g for 10 min. The supernatant subjected to retrospective diagnosis by a psychiatrist was stored on ice and the pellet rehomogenised in (CLEK), using hospital and Coroners’ records and inter- 0.25 M sucrose (1 : 10 w/v) and centrifuged at 750 g for views with the subject’s medical practitioner. Suicides 10 min. Combined supernatants were diluted with were divided into five groups according to the classi- 50 mM Tris-HCl buffer, pH 7.4 (at 25°C) to 1 : 100 w/v fication of Beskow et al.25 The subjects included in this and centrifuged at 35 000 g for 10 min. The membrane study came from group 1 (endogenous depression) and pellet was resuspended in 50 mM Tris-HCl buffer group 2 (depressive syndrome) only. Subjects from (1 : 50 w/v) and incubated at 37°C for 10 min to remove groups 3, 4 and 5, with diagnoses of schizophrenia, endogenous 5-HT, then centrifuged at 35 000 g for 10 personality disorder, epilepsy, alcohol or other drug min. The pellet was washed by resuspension in 50 mM abuse, alone or in combination with depression, and Tris-HCl buffer (1 : 100 w/v) and centrifuged at those with no clear psychiatric diagnosis, were 35 000 g for 10 min. The final pellet was resuspended excluded. Information on current and previous drug in 50 mM Tris-HCl buffer at a concentration of 5.3 mg treatment was sought and blood samples obtained at original wet weight ml−1 for cortical areas and post-mortem were analysed for the presence of psy- 2.6 mg ml−1 for putamen and globus pallidus, and choactive drugs. This information allowed two distinct immediately used in the binding assay. groups of suicides to be studied. Group 1. Antidepressant-free suicides (n = 20). These Binding assays subjects had not been prescribed antidepressant drugs Total 5-HT1, 5-HT1D/1E/1F and 5-HT1E/1F binding was within 3 months prior to death. Causes of death were determined concurrently (as previously described).20 hanging (n = 8), carbon monoxide poisoning (n = 5), Assays were performed in 5-ml plastic tubes. Drug sol- drug overdosage (n = 5), self-inflicted wounding (n = 1) utions were prepared in water, and ligand in 50 mM and jumping from height (n = 1). Control brains for this Tris-HCl buffer, pH 7.4 (at 25°C). Common to all assays group were from subjects who died suddenly from were 500 ml freshly prepared membranes, 100 mlof causes not involving the central nervous system, and 50 mM Tris-HCl buffer, pH 7.4 containing 4 mM cal- without documented evidence of mental illness. Con- cium chloride (final concentration) and 0.1% ascorb- trols were individually matched for age (75% within ate, 100 ml water (total binding) or unlabelled 5-HT 5 years) and gender. Causes of death were myocardial (10 mM, to define non-specific binding) and 100 ml infarction (n = 17), accidental fall (n = 1), acute asthma [3H]5-HT (25.4 Ci mmol−1, NEN Dupont, Boston, MA, (n = 1) and road traffic accident (n = 1). USA) at eight concentrations (0.5–32 nM final). 5- = Group 2. Antidepressant-treated suicides (n 16). HT1D/1E/1F binding sites were characterised by the pres- Prescription of antidepressant drugs was clearly docu- ence of 100 ml(−)pindolol (500 nM final) and 100 ml mented in this group. Details of drug treatment and mesulergine (100 nM final) to block 5-HT1A and 5-HT2C causes of death for these suicides are shown in Table 1. receptors respectively. (5-HT1B receptors are absent in 27 A second control group was individually matched for human brain.) 5-HT1E/1F binding was characterised by age (100% within 5 years) and gender to the antide- 100 ml 5-carboxamidotryptamine (5-CT, 100 nM final) m pressant-treated suicides.
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0179214 A1 Dubé Et Al
    US 20100179214A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0179214 A1 Dubé et al. (43) Pub. Date: Jul. 15, 2010 (54) DOXEPIN TRANS ISOMERS AND SOMERC continuation-in-part of application No. 1 1/804,720, MIXTURES AND METHODS OF USING THE filed on May 18, 2007. SAME TO TREAT SLEEP DSORDERS (60) Provisional application No. 60/898,378, filed on Jan. (75) Inventors: Susan E. Dubé, Carlsbad, CA (US); 30, 2007, provisional application No. 60/801,824, Neil B. Kavey, Chappaqua, NY filed on May 19, 2006, provisional application No. (US) 60/833,319, filed on Jul 25, 2006. Correspondence Address: KNOBBE MARTENS OLSON & BEAR LLP Publication Classification 2040 MAINSTREET, FOURTEENTH FLOOR (51) Int. Cl. IRVINE, CA 92.614 (US) A63L/335 (2006.01) A6IP 25/20 (2006.01) (73) Assignee: SOMAXON PHARMACEUTICALS, INC., (52) U.S. Cl. ........................................................ S14/450 San Diego, CA (US) (21) Appl. No.: 12/535,623 (57) ABSTRACT The invention relates to use of the trans-(E) isomer or iso (22) Filed: Aug. 4, 2009 meric mixtures containing specified ratios of the trans-(E) and cis-(Z) isomers of doxepin, metabolites of doxepin, phar Related U.S. Application Data maceutically-acceptable salts of doxepin and prodrugs of the (63) Continuation-in-part of application No. 12/022,788, same; compositions containing the same, for the treatment of filed on Jan. 30, 2008, now abandoned, which is a sleep disorders US 2010/0179214 A1 Jul. 15, 2010 DOXEPIN TRANS ISOMERS AND SOMERC brings scrutiny from the Drug Enforcement Administration MIXTURES AND METHODS OF USING THE and other regulatory bodies, and requires registration and SAME TO TREAT SLEEP DSORDERS administrative controls in physicians offices.
    [Show full text]
  • Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
    Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.
    [Show full text]
  • List of Vital Essential and Necessary Drugs and Medical Sundries For
    LIST OF VITAL ESSENTIAL AND NECESSARY DRUGS AND 2015 MEDICAL SUNDRIES FOR PUBLIC HEALTH INSTITUTIONS Sixth Edition STANDARDS & REGULATION DIVISION JAMAICA List of Vital Essential and Necessary List of Drugs and Medical Sundries for Public Institutions List of Vital Essential and Necessary List of Drugs and Medical Sundries for Public Institutions CONTENTS CONTENTS Contd. Page Preface 5-6 Page Information on Hospitals and Health Centres 7 Explanatory Notes 8 Medical Sundries 69-73 Prescription Writing 9-10 Dental Supplies 74 Algorithm for Treatment of Hypertension 11-12 Radiotherapy – Diagnostic Agents 75 Algorithm for Management of Type 2 Diabetes 13-14 Raw Materials 76 List of Drugs Designated for NHF 15-17 List of Drugs Designated for JADEP 18 VOLUME11 – SPECIALIST LIST 77 VOLUME 1 – GENERAL LIST 19 CLASSIFICATION OF DRUGS SECTION 1. Cardiovascular System 78 CLASSIFICATION OF DRUGS SECTION 2. Central Nervous System 79 SECTION 1. Cardiovascular System 20-24 SECTION 3. Dermatology 80 SECTION 2. Central Nervous System 25-30 SECTION 4. Endocrine System 80 SECTION 3. Dermatology 31-33 SECTION 5. Gastro-intestinal System 81 SECTION 4. Ear, Nose and Oropharynx 34-35 SECTION 6. Infections 81 SECTION 5. Endocrine System 36-38 SECTION 7. Malignant Disease and SECTION 6. Gastro-intestinal System 39-40 Immunosuppression 82 SECTION 7. Infections 41-46 SECTION 8. Musculoskeletal and Joint Diseases 83 SECTION 8. Malignant Disease and SECTION 9. Ophthalmology 83 Immunosuppression 47-49 SECTION 10. Genito-Urinary Tract Disorders 84 SECTION 9. Musculoskeletal and Joint Diseases 50-51 SECTION 11. Respiratory System 84 SECTION 10. Nutrition and Blood 52-54 SECTION 12.
    [Show full text]
  • A General Approach to the Screening and Confirmation of Tryptamines And
    Available online at www.sciencedirect.com Talanta 74 (2008) 512–517 A general approach to the screening and confirmation of tryptamines and phenethylamines by mass spectral fragmentation Bo-Hong Chen a, Ju-Tsung Liu b, Wen-Xiong Chen a, Hung-Ming Chen a, Cheng-Huang Lin a,∗ a Department of Chemistry, National Taiwan Normal University, 88 Sec. 4, Tingchow Road, Taipei, Taiwan b Forensic Science Center, Military Police Command, Department of Defense, Taipei, Taiwan Received 6 March 2007; received in revised form 12 June 2007; accepted 13 June 2007 Available online 19 June 2007 Abstract Certain characteristic fragmentations of tryptamines (indoleethylamine) and phenethylamines are described. Based on the GC–EI/MS, LC–ESI/ MS and MALDI/TOFMS, the mass fragmentations of 13 standard compounds, including ␣-methyltryptamine (AMT), N,N-dimethyltryptamine (DMT), 5-methoxy-␣-methyltryptamine (5-MeO-AMT), N,N-diethyltryptamine (DET), N,N-dipropyltryptamine (DPT), N,N-dibutyltryptamine (DBT), N,N-diisopropyltryptamine (DIPT), 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), 5-methoxy-N,N-diisopropyltryptamine (5-MeO- DIPT), methamphetamine (MAMP), 3,4-methylenedioxyamphetamine (3,4-MDA), 3,4-methylenedioxymethamphetamine (3,4-MDMA) and 2- methylamino-1-(3,4-methylenedioxyphenyl)butane (MBDB), were compared. As a result, the parent ions of these analytes were hard to be obtained by GC/MS whereas the protonated molecular ions can be observed clearly by means of ESI/MS and MALDI/TOFMS. Furthermore, two major + + + + characteristic fragmentations, namely and ␣-cleavage ([M +H] → [3-vinylindole] ) and ␤-cleavage ([M +H] → [CH2N RN1RN2]), are produced when the ESI and MALDI modes are used, respectively. In the case of ESI/MS, the fragment obtained from ␣-cleavage is the major process.
    [Show full text]
  • Copyrighted Material
    Index Note: page numbers in italics refer to figures; those in bold to tables or boxes. abacavir 686 tolerability 536–537 children and adolescents 461 acamprosate vascular dementia 549 haematological 798, 805–807 alcohol dependence 397, 397, 402–403 see also donepezil; galantamine; hepatic impairment 636 eating disorders 669 rivastigmine HIV infection 680 re‐starting after non‐adherence 795 acetylcysteine (N‐acetylcysteine) learning disability 700 ACE inhibitors see angiotensin‐converting autism spectrum disorders 505 medication adherence and 788, 790 enzyme inhibitors obsessive compulsive disorder 364 Naranjo probability scale 811, 812 acetaldehyde 753 refractory schizophrenia 163 older people 525 acetaminophen, in dementia 564, 571 acetyl‐L‐carnitine 159 psychiatric see psychiatric adverse effects acetylcholinesterase (AChE) 529 activated partial thromboplastin time 805 renal impairment 647 acetylcholinesterase (AChE) acute intoxication see intoxication, acute see also teratogenicity inhibitors 529–543, 530–531 acute kidney injury 647 affective disorders adverse effects 537–538, 539 acutely disturbed behaviour 54–64 caffeine consumption 762 Alzheimer’s disease 529–543, 544, 576 intoxication with street drugs 56, 450 non‐psychotropics causing 808, atrial fibrillation 720 rapid tranquillisation 54–59 809, 810 clinical guidelines 544, 551, 551 acute mania see mania, acute stupor 107, 108, 109 combination therapy 536 addictions 385–457 see also bipolar disorder; depression; delirium 675 S‐adenosyl‐l‐methionine 275 mania dosing 535 ADHD
    [Show full text]
  • Detection of Phenethylamine, Amphetamine, and Tryptamine Imine By-Products from an Acetone Extraction
    Detection of Phenethylamine, Amphetamine, and Tryptamine Imine By-Products from an Acetone Extraction Mary A. Yohannan* and Arthur Berrier U.S. Department of Justice Drug Enforcement Administration Special Testing and Research Laboratory 22624 Dulles Summit Court Dulles, VA 20166 [email: mary.a.yohannan -at- usdoj.gov] ABSTRACT: The formation of imine by-products from phenethylamines, amphetamines, and tryptamines upon an acetone extraction is presented. These imine by-products were characterized using GC/MSD and exhibited preferential cleavage at the α-carbon of the alkyl chain. Further characterization of the imine by-products of phenethylamine and tryptamine was done using IR and NMR. KEYWORDS: phenethylamine, tryptamine, imine, acetone, schiff base, drug chemistry, forensic chemistry In most forensic laboratories, the solvents used to extract at the α-carbon on the alkyl chain. In addition to GC/MS, the drugs are chosen based upon their solubility properties and their imines formed from phenethylamine base and tryptamine base ability to not interact with the drug. In fact, there are very few were characterized by Fourier transform-infrared spectroscopy publications where a solvent used to extract a drug reacts with (FTIR) and nuclear magnetic resonance (NMR) spectroscopy. the drug and forms by-products [1-3]. This laboratory recently discovered that an additional Experimental component was formed when acetone was used to extract a Solvents, Chemicals, and Materials sample containing a known tryptamine. Analysis by gas Acetone was ACS/HPLC grade from Burdick and Jackson chromatography/mass spectroscopy (GC/MS) of the acetone Laboratories (Muskegon, MI). Phenethylamine base and extract yielded an extra peak in the total ion chromatogram that tryptamine base were obtained from Sigma-Aldrich Chemicals was approximately half the abundance of the known tryptamine (Milwaukee, WI).
    [Show full text]
  • A Phase 3, Multicenter, Randomized, Double-Blind
    Official Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment NCT Number: NCT03999918 Document Date: 21 Jun 2020 CLINICAL STUDY PROTOCOL UNMASKED PROTOCOL A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment Protocol Number: ACP-103-054 Amendment 4 EudraCT Number: 2018-003251-37 Original Protocol Date: 30 August 2018 Protocol Amendment 1 Date: 05 December 2018 Protocol Amendment 2 Date: 18 March 2019 Protocol Amendment 3 Date: 29 October 2019 Protocol Amendment 4 Date: 21 June 2020 Confidentiality Statement This protocol is the confidential information of ACADIA Pharmaceuticals Inc. and is intended solely for the guidance of the clinical investigation. This protocol may not be disclosed to parties not associated with the clinical investigation or used for any purpose without the prior written consent of ACADIA Pharmaceuticals Inc. Confidential and Proprietary Information of ACADIA Pharmaceuticals Inc. Page 1 of 81 Study: ACP-103-054 Final Version: 1.0 Clinical Study Protocol Amendment 4 UNMASKED VERSION Date: 21 June 2020 SPONSOR SIGNATURE PAGE Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment ACADIA President: President ACADIA Pharmaceuticals Inc. See appended electronic signature page Signature Date ACADIA Study Lead: Executive Director, Clinical Research ACADIA Pharmaceuticals Inc.
    [Show full text]
  • Hallucinogens: an Update
    National Institute on Drug Abuse RESEARCH MONOGRAPH SERIES Hallucinogens: An Update 146 U.S. Department of Health and Human Services • Public Health Service • National Institutes of Health Hallucinogens: An Update Editors: Geraline C. Lin, Ph.D. National Institute on Drug Abuse Richard A. Glennon, Ph.D. Virginia Commonwealth University NIDA Research Monograph 146 1994 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service National Institutes of Health National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 ACKNOWLEDGEMENT This monograph is based on the papers from a technical review on “Hallucinogens: An Update” held on July 13-14, 1992. The review meeting was sponsored by the National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other material in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors. Citation of the source is appreciated. Opinions expressed in this volume are those of the authors and do not necessarily reflect the opinions or official policy of the National Institute on Drug Abuse or any other part of the U.S. Department of Health and Human Services. The U.S. Government does not endorse or favor any specific commercial product or company.
    [Show full text]
  • Total Synthesis Method for Making an Indole Structure Derivative Product
    Europa,schesP_ MM M II M MM M II II MM MM II J European Patent Office _ _ _ _ _ _ © Publication number: 0 330 625 B1 Office_„. europeen des brevets © EUROPEAN PATENT SPECIFICATION © Date of publication of patent specification: 20.12.95 © Int. CI.6: C07D 209/16, A61 K 31/40 © Application number: 89830055.3 @ Date of filing: 16.02.89 Total synthesis method for making an indole structure derivative product class, of the triptamine type, in particular, melatonin or N-acetyl-5-methoxytriptamine type, having a high purity degree and easily soluble, for therapeutic use against acquired immuno-deficiency syndromes © Priority: 25.02.88 IT 1954988 rivatives of tryptamines",& J. CHROMATOGR. 08.09.88 IT 21 87288 SCI. 1 977, 1 5(5), 1 81 -4 @ Date of publication of application: © Proprietor: I.F.L.O. S.a.s. di Giorgio e Aldo 30.08.89 Bulletin 89/35 Laguzzi Via Prandina, 7 © Publication of the grant of the patent: 1-20127 Milano (IT) 20.12.95 Bulletin 95/51 @ Inventor: Fraschini, Franco © Designated Contracting States: Via Prandina, 7 AT BE CH DE ES FR GB GR LI NL SE 1-20127 - Milano (IT) Inventor: Di Bella, Luigi © References cited: Via Prandina, 7 DE-A- 3 105 850 1-20127 - Milano (IT) Inventor: Duranti, Ermanno CHEMICAL ABSTRACTS, vol. 82, no. 21, 26th Via Prandina, 7 May 1975, page 605, abstract no.139888g, 1-20127 - Milano (IT) Columbus, Ohio, US; N.N. SUVOROV et al.: "Indole derivatives. Cl.Synthesis and biologi- cal activity of some tryptamines",& KHIM.
    [Show full text]
  • Update of the Generic Definition for Tryptamines
    ACMD Advisory Council on the Misuse of Drugs Chair: Professor Les Iversen Secretary: Zahi Sulaiman 2nd Floor (NW), Seacole Building 2 Marsham Street London SW1P 4DF Tel: 020 7035 1121 [email protected] Norman Baker MP, Minister for Crime Prevention Home Office 2 Marsham Street London SW1P 4DF 10 June 2014 Dear Minister, In December 2013, you commissioned the ACMD to begin a regular review of generic definitions under the Misuse of Drugs Act 1971, with the aim of capturing emerging new psychoactive substances. These drugs are variants of controlled drugs and fall outside the existing scope of the Misuse of Drugs Act 1971. The ACMD has considered evidence available on tryptamines in the context of the Misuse of Drugs Act 1971 and I enclose the Advisory Council’s advice and an expanded definition for tryptamine compounds with this letter. The ACMD’s NPS Committee has firstly reviewed previous research and existing controls to identify those tryptamines now seen to evade the existing controls. The ACMD has also reviewed data provided by the Home Office’s early warning systems and networks, clinical toxicology, prevalence and neuropharmacology in arriving at the expanded generic definition. This expanded generic definition will bring drugs such as alpha-methyltryptamine (AMT) as well as 5-MeO-DALT within the scope of the Misuse of Drugs Act 1971. These are highly potent hallucinogens which act on the 5HT2A receptor, in the same way as LSD. The ACMD therefore recommends that the tryptamines covered by the proposed expanded generic definition in this report, are controlled under the Misuse of Drugs Act (1971) as Class A substances.
    [Show full text]
  • N,N-Dimethyltryptamine Compound Found in the Hallucinogenic Tea Ayahuasca, Regulates Adult Neurogenesis in Vitro and in Vivo Jose A
    Morales-Garcia et al. Translational Psychiatry (2020) 10:331 https://doi.org/10.1038/s41398-020-01011-0 Translational Psychiatry ARTICLE Open Access N,N-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo Jose A. Morales-Garcia 1,2,3,4, Javier Calleja-Conde 5, Jose A. Lopez-Moreno 5, Sandra Alonso-Gil1,2, Marina Sanz-SanCristobal1,2, Jordi Riba6 and Ana Perez-Castillo 1,2,4 Abstract N,N-dimethyltryptamine (DMT) is a component of the ayahuasca brew traditionally used for ritual and therapeutic purposes across several South American countries. Here, we have examined, in vitro and vivo, the potential neurogenic effect of DMT. Our results demonstrate that DMT administration activates the main adult neurogenic niche, the subgranular zone of the dentate gyrus of the hippocampus, promoting newly generated neurons in the granular zone. Moreover, these mice performed better, compared to control non-treated animals, in memory tests, which suggest a functional relevance for the DMT-induced new production of neurons in the hippocampus. Interestingly, the neurogenic effect of DMT appears to involve signaling via sigma-1 receptor (S1R) activation since S1R antagonist blocked the neurogenic effect. Taken together, our results demonstrate that DMT treatment activates the subgranular neurogenic niche regulating the proliferation of neural stem cells, the migration of neuroblasts, and promoting the generation of new neurons in the hippocampus, therefore enhancing adult neurogenesis and
    [Show full text]
  • Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)
    Model Scheduling New/Novel Psychoactive Substances Act (Third Edition) July 1, 2019. This project was supported by Grant No. G1799ONDCP03A, awarded by the Office of National Drug Control Policy. Points of view or opinions in this document are those of the author and do not necessarily represent the official position or policies of the Office of National Drug Control Policy or the United States Government. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws. Please contact NAMSDL at [email protected] or (703) 229-4954 with any questions about the Model Language. This document is intended for educational purposes only and does not constitute legal advice or opinion. Headquarters Office: NATIONAL ALLIANCE FOR MODEL STATE DRUG 1 LAWS, 1335 North Front Street, First Floor, Harrisburg, PA, 17102-2629. Model Scheduling New/Novel Psychoactive Substances Act (Third Edition)1 Table of Contents 3 Policy Statement and Background 5 Highlights 6 Section I – Short Title 6 Section II – Purpose 6 Section III – Synthetic Cannabinoids 13 Section IV – Substituted Cathinones 19 Section V – Substituted Phenethylamines 23 Section VI – N-benzyl Phenethylamine Compounds 25 Section VII – Substituted Tryptamines 28 Section VIII – Substituted Phenylcyclohexylamines 30 Section IX – Fentanyl Derivatives 39 Section X – Unclassified NPS 43 Appendix 1 Second edition published in September 2018; first edition published in 2014. Content in red bold first added in third edition. © 2019 NATIONAL ALLIANCE FOR MODEL STATE DRUG LAWS. This document may be reproduced for non-commercial purposes with full attribution to the National Alliance for Model State Drug Laws.
    [Show full text]